Integration of histone modification-based risk signature with drug sensitivity analysis reveals novel therapeutic strategies for lower-grade glioma.

Journal: Frontiers in pharmacology
Published Date: Jan 13, 2025

Abstract

BACKGROUND: Lower-grade glioma (LGG) exhibits significant heterogeneity in clinical outcomes, and current prognostic markers have limited predictive value. Despite the growing recognition of histone modifications in tumor progression, their role in LGG remains poorly understood. This study aimed to develop a histone modification-based risk signature and investigate its relationship with drug sensitivity to guide personalized treatment strategies.

Authors

  • Jingyuan Wang
    Department of Neurological Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China.
  • Shuai Yan
    Department of Neurological Function Examination, Affiliated Hospital of Hebei University, Baoding, China.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals